HIV Infections
Conditions
Keywords
Pharmacokinetics, atazanavir, saquinavir, ritonavir, HIV
Brief summary
Saquinavir and Atazanavir are drugs used in combination therapy to treat HIV disease. Saquinavir is currently available in a 200 milligram capsule. Most individuals currently on saquinavir require to take 5 tablets twice a day. In an attempt to reduce this number of pills, a new capsule has been developed containing 500 milligrams of saquinavir. This study will assess: i) blood drug levels in individuals taking both saquinavir formulations, ii) blood drug levels in individuals taking both saquinavir formulations when given with atazanavir, iii) 48 weeks of follow up for individuals receiving the new saquinavir formulation with atazanavir as HIV therapy.
Detailed description
BACKGROUND The development of anti-HIV therapy for the treatment of HIV disease has improved the quality of life and survival of many people with HIV. However the treatments do not always work over long periods, as medications are often difficult to take due to side effects and a large numbers of pills to be taken. This has lead researchers to look for new ways to treat HIV with medications that require fewer numbers of pills and have fewer side effects. Atazanavir and saquinavir are two drugs used to treat HIV and come from the same class of drugs known as the protease inhibitors. Atazanavir has the advantage of being taken only once a day. Saquinavir is available in a new formulation (type of pill), which will require fewer numbers of pills to be taken daily. AIM The purpose of this study is to investigate the use of these two drugs used together with ritonavir as a once daily HIV treatment, which will consist of 6 tablets. Furthermore this study will look at blood drug levels in individuals on atazanavir, saquinavir and ritonavir with and without the new saquinavir formulation to ensure blood levels of these drugs are adequate. For individuals currently on the old saquinavir formulation, this study will also look at blood drug levels before and after changing to the new formulation.
Interventions
DRUGsaquinavir 500 formulation
NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
DRUGcross-over arm
either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
Sponsors
Hoffmann-La Roche
Kirby Institute
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
HIV-1 infected individuals aged 18 years or over On stable antiretroviral therapy for at least three months consisting of nucleoside reverse transcriptase inhibitors and protease inhibitors OR On stable antiretroviral therapy for at least three months consisting of atazanavir-saquinavir-ritonavir Undetectable HIV RNA viral load for past three months
Exclusion criteria
* Individuals receiving on non-nucleoside reverse transcriptase inhibitors within the past three months * Individuals currently receiving other enzyme inducing agents (as per * Individuals receiving ritonavir at doses greater than 100 mg bid * Active AIDS defining illnesses * Previously documented intolerance or virological failure to saquinavir * Previously documented intolerance or virological failure to atazanavir * Patients who are co-infected with Hepatitis B and are likely to require, in their clinician's opinion, HBV nucleoside therapy during the study. * Female patients who are pregnant, breastfeeding, or who plan to become pregnant during the study * Any current clinical or laboratory parameter of ACTG Grade 4 (except lipids & CK) * Evidence of ongoing alcohol and/or drug or substance abuse that would result in the patient being unreliable in fulfilling the conditions of this protocol * Prior non-adherence to antiretroviral treatment regimens that would result in the patient being unreliable in fulfilling the conditions of this protocol * Evidence of active opportunistic infection, intercurrent illness, drug toxicity or any other condition that would preclude the patient from taking the prescribed antiretroviral regimen * Conditions that might interfere with evaluation of the disease under study. * Conditions/allergies that may compromise the safety of the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the decay pharmacokinetics | week 48 |
| To compare the pharmacokinectic profile of ATV-SQV-RTV using SQV 500 and 200 formulations. | week 48 |
| To compare the pharmacokinetic profile of SQV/r 1000/100mg bid using SQV 500 and 200 formulations. | week 48 |
| To assess the durability and safety of a once daily double boosted PI regimen comprised of ATV300 - SQV1500 - RTV100 | week 48 |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of adherence to medications. | week 48 |
| Assessment of changes to CD4 lymphocyte count | week 48 |
| Assessment of changes in lipid parameters | week 48 |
| Assessment of changes in monocyte mRNA | week 48 |
Countries
Australia
Outcome results
None listed